62
Diabetes mellitus in children By Henry Cummings MBBS, FMCPaed Delsuth, Oghara

Diabetes mellitus in children By Henry Cummings MBBS, FMCPaed Delsuth, Oghara

Embed Size (px)

Citation preview

  • Slide 1
  • Slide 2
  • Diabetes mellitus in children By Henry Cummings MBBS, FMCPaed Delsuth, Oghara
  • Slide 3
  • Pre-test 1. Dm is the commonest endocrine disorder in children 2. Only type 1 dm occurs in children 3. TIDm is a non progressive low-insulin catabolic state 4. Exogenous insulin replacement remains the only form of replacement therapy 5. In managing DKA, always add kcl to the initial rehydrating fluid.
  • Slide 4
  • Childhood Diabetes mellitus Definition Types Patho physiology Clinical features Modalities of management Complications, short term, long term Recent advancements Conclusion
  • Slide 5
  • DEFINITION BY WHO: DM is a metabolic disorder of multiple aetiologies characterised by chronic disturbances of carbohydrate, fat & protein metabolism, resulting from defects in insulin secretion, insulin action or both. DM is the commonest endocrine disease in childhood & adolescence.
  • Slide 6
  • MAGNITUDE OF THE PROBLEM Overall incidence 1 to 2 per 1000 school age children. Estimated prevalence of childhood DM in 2003 were: 430,000 globally 250,000 live developing countries. 63,000 live in 58 poorest countries(least developed countries).
  • Slide 7
  • TYPES OF DM Type 1 DM(IDDM) Beta cell autoimmune destruction Absolute insulin deficiency Requires insulin for survival Accounts for over 90% of childhood DM Peak age incidence 10-12 years Slight male predominance Prone to ketosis
  • Slide 8
  • Type 2 DM (NIDDM) Insulin resistance with relative deficiency OR Secretory defect with or without resistance Does not require insulin for survival Strong genetic component Not prone to ketosis Acanthosis nigrans may be present No islet cell antibodies Associated with overweight teenagers
  • Slide 9
  • Maturity onset diabetes of the youth (MODY) Early onset of dominantly inherited type 2 DM Non- obese children No islet cell antibodies Family history in several generation Identified genetic mutations e.g mutations of glucokinase or hepatic nuclear factor 1 & 2 genes Non- ketotic Two (or at least one)family member diagnosed before age of 25 years
  • Slide 10
  • Neonatal Diabetes hyperglycemia requiring insulin in the first 3months of life Rare condition 1:400,000 Associated with IUGR 50% of cases are transient Associated with paternal isodomy & other imprinting defects of Chr 6 In transient NND permanent DM may appear later in life
  • Slide 11
  • Secondary diabetes mellitus May be associated with cystic fibrosis, hemochromatosis, drugs such as L- Asparaginase
  • Slide 12
  • Criteria for diagnosis Symptoms of DM and casual plasma glucose conc > 11.1mmol/L(200mg/dl) (10 for venous) FPG > 7.0mmol/L(126mg/dl) (6.3 for venous and cap) 2hr post load of glucose >11.1mmol/L during an OGTT
  • Slide 13
  • blood sugars blood sugars Normal RPG: 70 140mg/dl Normal FBS:70 100mg/dl Hypoglycemia: Mild40 70mg/dl Severe40mg/dl Neonatal
  • Slide 14
  • Etiology of T1Diabetes Environmental Factors Cows milk? Viruses ? Nitrates? Genetic Susceptibility DM1: HLADR3,DR4 Protective DRB1,DQB1 DM2 Autoimmunity & Insulitis Destruction of pancreatic cells
  • Slide 15
  • Pathophysiology Insulin essential to process CHO, fat, protein It blood glucose levels by glucose uptake into muscle cells and fat cells stimulates glycogenesis inhibits glycogenolysis the breakdown of fat to triglycerides, free fatty acids, and ketones. (lipolysis)
  • Slide 16
  • Pathophysiology Lack of Insulin glucose oxidation in muscle & fat cells Proteolysis & amino acid release Glycogenolysis & gluconeogenesis all result in Hyperglycaemia Glucose intake still continues
  • Slide 17
  • Pathophysiology The kidneys cannot reabsorb the excess glucose load, causing glycosuria, osmotic diuresis(polyuria), thirst, and dehydration. Untreated pt excrete high glucose load causing polyphagia Increased fat and protein breakdown leads to ketone production and weight loss.
  • Slide 18
  • Pathophysiology contd Acidosis result from ketosis Acidosis leads to renal excretion of K + and Po 4 Na + loss is due to osmotic diuresis & vomiting Hypokalemia is due to vomiting, osmotic diuresis & hyperaldosteronism Coma likely due to ketosis, acidosis, dehydration & hyperosmolality
  • Slide 19
  • Absolute insulin deficiency OR Stress, infection or insufficient insulin intake Counter-regulatory hormones: Glucagon, Cortisol, Catecholamines, GH Lipolysis FFA to liver Ketogenesis Alkali reserve Acidosis Lactate Glucose utilization Proteolysis Protein synthesis Glycogenolysis Gluconeogenic substrates Gluconeogenesis Hyperglycemia Glucosuria (osmotic diuresis) Loss of water and electrolytes Dehydration Impaired renal function Hyperosmolarity
  • Slide 20
  • Phases of T1DM 1. Preclinical diabetes 2. Presentation of DM 3. Partial remission or honeymoon phase 4. Chronic phase of lifelong dependency on administered insulin
  • Slide 21
  • Preclinical DM Occurs months to years preceding the clinical presentation of T1DM Antibodies can be detected as markers of beta cell auto immunity:- GAD, IA,ICA, IA2 etc IVGTT
  • Slide 22
  • T1DM: a slowly progressive T-cell mediated autoimmune illness Genetic susceptibility Islet Cell Mass 100% 50% 0% Inciting Event(s)Diabetes I II III Time (years) Silent Cell Loss Diabetes Onset cell Mass?? Is cell loss exclusively immune mediated?
  • Slide 23
  • Clinical presentation Vary from non-emergency px( polydipsia, polyuria, weight loss, enuresis) to severe dehydration, shock and DKA Onset may be acute, precipitated by an acute illness, or more chronic and insidious over weeks or even months.
  • Slide 24
  • Lab Investigations Glucose levels E & U Ketones C peptides Islets cell antibodies
  • Slide 25
  • Other Lab Investigations Lipids Microalbumin Thyroid fxn test Hb A1c fructosamine
  • Slide 26
  • Modalities of management requires Multidisciplinary team Insulin therapy Diabetic education Exercise Diet Psychological care Monitoring Others:- sick day mx, adjusting to school
  • Slide 27
  • Insulin therapy Exogenous insulin replacement remains the only form of replacement therapy
  • Slide 28
  • The Basal/bolus Insulin Concept Basal Insulin - Suppresses glucose production btw meals and overnight -40% to 50% of daily needs Bolus Insulin (meal time) -Limits hyperglycaemia after meals -Immediate rise and sharp peak at 1 hour -50% -60% total daily insulin requirement for meals
  • Slide 29
  • Basal/bolus therapy regimens Intensive management : MDI Multiple Dose Insulin Once-daily IA or LA insulin usually given at night and 3-ce daily SA or VA before each meal Mixed preps e.g. Mixtard, humulin 70/30 CSII Continuous Subcutaneous Insulin Infusion (Insulin pump therapy)
  • Slide 30
  • INSULIN THERAPY contd. Twice daily regimen: Split dose regimen (2/3 morning, 1/3 evening; 2/3 intermediate acting, 1/3 soluble). Aim at maintaining blood glucose within 80-150mg/dl, with the occurrence of as few hypoglycaemic episodes as possible.
  • Slide 31
  • Twice a day insulin Soluble insulin Intermediate- acting insulin Insulin 60 0 20 40 Endogenous insulin BreakfastLunchSupper
  • Slide 32
  • DIET Complex carbohydrates (CBHs) are preferred to simple refined CBHs. Dietary regimen should be adjusted according to convenience of the family and school timings to ensure better compliance. Total CBH content of the meal &snacks should be kept constant.
  • Slide 33
  • EXERCISE Encourage regular exercise. Insulin requirement may be lower, metabolic control improved and self- esteem & body image better in physically fit child.
  • Slide 34
  • SELF- CARE EDUCATION Should include nature of illness, acute & chronic complications, insulin action, duration and timing, injection techniques, nutrition information, self blood glucose monitoring and urine ketone checks. Education must be appropriate to childs age & family educational background.
  • Slide 35
  • Monitoring Monitoring of growth & development: the use of percentile charts is a crucial element in the care of children & adolescents with DM Poor gain of height & weight, hepatomegaly and delayed puberty might be seen in children with persistently poorly controlled DM
  • Slide 36
  • Monitoring HbA1c at least twice a year Screening for long term complications
  • Slide 37
  • Partial remission (honeymoon) phase Defined as when the patient requires < 0.5units of insulin/kg/day and has an HbA1c
  • Diagnosis 3 cardinal features: 1.Hyperglycemia - >200mg/dl(11.1mmol/l) 2.Ketonuria >5mmol/l, ketonemia 3.Venous ph
  • TREATMENT contd Maintain IV insulin until DKA resolves: pH > 7.3, bicarbonate > 15mmol/L, stable serum Na+ 135 145mmol/L, No emesis; then switch to SC insulin (maintain IV insulin 30min after SC) Ketones may take longer to clear
  • Slide 53
  • HYPOKALEMIC = give with initial resuscitation 20mmol/l EUKALEMIC = at the time of insulin intro HYPERKALEMIC = when patient makes urine POTASSIUM
  • Slide 54
  • Max dose 0.5mmol/kg/hr If hypokalemia persist then reduce insulin infusion rate! ECG monitoring helps! Potassium
  • Slide 55
  • Is given cautiously only if pH < 6.9 HCO3 < 5mmol/l 1 2mmol/kg over one hour! Acidosis
  • Slide 56
  • Hourly monitoring and charting of Blood pressure Respiratory rate Heart rate Level of consciousness Blood sugar Blood ketones Electrolyte and urea(Ca,PO4,Mg) Input /output Insulin given Monitoring/charting
  • Slide 57
  • Inadequate rehydration Hypoglycemia Hypokalemia hypophosphatemia Cerebral edema Complications of therapy
  • Slide 58
  • Management of DKA Follow up
  • Slide 59
  • PG >33.3 mmol/L (600 mg/dL) Arterial pH >7.30 Serum bicarbonate >15 mmol/L Small ketonuria, absent to low ketonemia Effective serum osmolality >320 mOsm/kg Stupor or coma HHS (Hyperglycemic hyperosmolar state)
  • Slide 60
  • Long-term complications Retinopathy Cataracts Hypertension Progressive renal failure Early coronary artery disease Peripheral vascular disease Neuropathy, both peripheral and autonomic Increased risk of infection Injection-site hypertrophy Growth failure. Delayed puberty
  • Slide 61
  • Recent advancements Whole pancreas transplantation Islet cell transplantation Engineered stem cells manipulated genetically to produce insulin Techniques to protect b cells from autoimmune attack Immunotherapy Alternate non invasive routes for insulin administration Chemical alteration of insulin molecule Artificial pancreas Adding c peptide to insulin Implantable insulin pumps New blood glucose meters
  • Slide 62
  • Conclusion DM (particularly T1DM), a common and potentially life threatening endocrine disorder in children is often misdiagnosed or poorly managed Having a regularly updated management protocol in our Paediatric units will greatly improve the level and quality of care these children receive. Thank you for listening.
  • Slide 63
  • Post test 1. Dm is the commonest endocrine disorder in children 2. Only type 1 dm occurs in children 3. TIDm is a non progressive low-insulin catabolic state 4. Exogenous insulin replacement remains the only form of replacement therapy 5. In managing DKA, always add kcl to the initial rehydrating fluid.